Sector News

Big pharma accused of price gouging life-saving drugs

January 3, 2018
Life sciences

Last January, shortly before his presidency began, Donald Trump promised to end big pharmaceutical companies’ stranglehold on drug prices and the healthcare industry; but more than a year later, drug companies continue to face almost no competition while steadily raising their prices.

Amgen raised the price of its rheumatoid arthritis drug Enbrel by 9.7%; Biogen tacked on another 8% to its multiple sclerosis drugs — among them the popular Avonex — and perhaps the most stunning: NextSource, which raised the price of its 40-year-old life-extending cancer drug Lomustine by 1,400%.

One of the main reasons that pharmaceutical companies can manage to hike prices so much is because of a lack of competition, Chip Davis, CEO of the Association for Accessible Medicines told FOX Business’ Liz Claman. Currently, 319 drugs on the market have no cheaper competitors in the form of generics.

“The reality is, ultimately, policymakers are going to have to decide whether there’s things they can do to enhance the market,” Davis said. “Or, simply, they’re going to revert to the heavy-hand of government, which is something we don’t support.”

Government officials have faced accusations of aiding the pharmaceutical industry by accepting donations to campaigns. During the 2016 election cycle, 97 senators and 399 members of the House received contributions from the pharmaceutical and health products sector.

But in mid-October, the U.S. Food and Drug Administration, under the tutelage of Trump-appointed Commissioner Scott Gottlieb, announced a series of measures designed to accelerate the availability of generic versions of drugs such as Mylan’s (NASDAQ: MYL) EpiPen in hopes of deterring the rising cost of pharmaceuticals. Mylan garnered national attention in 2016 when it came to light that two EpiPens — the life-saving medication used to combat severe allergy attacks — had increased from $57 in 2007 to more than $700 in 2016. EpiPens cost less than $2 to produce.

Gottlieb believes in utilizing a market-based solution to combat expensive drug prices, Davis said. That means he’ll likely try to prioritize the availability of generics — which already account for 89% of prescriptions written in the country — by approving applications for medicines where there are no generics.

“We are currently experiencing unprecedented levels of deflation in the generic sector,” he said. “Otherwise, the increases in prices among the branded industry would be having a far greater impact.”

Source: Fox Business

comments closed

Related News

April 20, 2025

FDA cuts outlined in draft HHS budget

Life sciences

Politico’s Agency IQ reported earlier this month that, due to the Trump administration’s laying off of thousands of staffers, the FDA risked hitting a “trigger,” whereby the FDA could be required to refund industry fees if spending by the agency falls below a certain level.

April 20, 2025

Big pharma pushes for European policy change as tariffs loom

Life sciences

Pharmaceutical companies are demanding changes in European regulation as looming tariffs implemented by US President Donald Trump “threaten” billions of planned pharma investments on the continent. A group of 32 pharma companies sent a letter to European Commission (EC) President Ursula von der Leyen listing requests to avoid an exodus of operations.

April 20, 2025

Boehringer Ingelheim announces leadership changes in shareholders’ committee and board

Life sciences

Christian Boehringer, Chairman of the Shareholders’ Committee since 2007, has decided to step down from his position as of June 30, 2025. The Shareholders’ Committee has appointed Hubertus von Baumbach, currently Chairman of the Board of Directors, as his successor from July 1, 2025.

How can we help you?

We're easy to reach